Henry Schein, Inc. (NASDAQ:HSIC) saw a significant growth in short interest during the month of March. As of March 29th, there was short interest totalling 19,816,414 shares, a growth of 15.4% from the March 15th total of 17,167,594 shares. Approximately 13.1% of the company’s shares are sold short. Based on an average trading volume of 1,937,250 shares, the days-to-cover ratio is currently 10.2 days.
Shares of NASDAQ:HSIC opened at $68.98 on Friday. Henry Schein has a 1 year low of $62.56 and a 1 year high of $93.50. The company has a market cap of $10,657.90, a price-to-earnings ratio of 19.16, a price-to-earnings-growth ratio of 1.69 and a beta of 1.05. The company has a quick ratio of 0.76, a current ratio of 1.45 and a debt-to-equity ratio of 0.32.
Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, February 20th. The company reported $0.97 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.97. Henry Schein had a return on equity of 19.70% and a net margin of 3.26%. The business had revenue of $3.32 billion during the quarter, compared to analyst estimates of $3.30 billion. During the same quarter in the previous year, the business earned $0.94 earnings per share. The company’s revenue for the quarter was up 6.3% compared to the same quarter last year. analysts anticipate that Henry Schein will post 4.09 EPS for the current fiscal year.
Several equities research analysts have weighed in on HSIC shares. Piper Jaffray reissued a “buy” rating and set a $78.00 price objective on shares of Henry Schein in a research note on Wednesday, December 27th. Barclays started coverage on Henry Schein in a research note on Thursday, March 8th. They set an “equal weight” rating and a $71.00 price objective on the stock. Zacks Investment Research cut Henry Schein from a “buy” rating to a “hold” rating in a research note on Tuesday, March 6th. Leerink Swann reissued a “hold” rating on shares of Henry Schein in a research note on Tuesday, February 13th. Finally, JPMorgan Chase reissued a “neutral” rating and set a $77.00 price objective (down from $79.00) on shares of Henry Schein in a research note on Thursday, February 15th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $82.31.
ILLEGAL ACTIVITY WARNING: This piece of content was first posted by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://dakotafinancialnews.com/2018/04/14/henry-schein-inc-hsic-sees-significant-increase-in-short-interest.html.
Henry Schein Company Profile
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.